Advances In™ Personalizing MS Management Plans: Strategies for Optimizing Long-Term Patient Outcomes in MS and Individualizing Treatment within the S1P Receptor Modulator Class

CME: 1.0

Target Audience

This educational activity is directed toward neurologists and other health care providers who care for patients with MS.

Program Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of multiple sclerosis (MS) with a forward-looking perspective on how new and novel agents might impact clinical practice. The integration of biomarkers into diagnosis, efficacy of various disease-modifying therapies with a focus on the sphingosine-1-phosphate receptor modulator (S1PRM) class, and patient-focused risk assessment are presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess the role of potential biomarkers and other key indicators of multiple sclerosis (MS) related to early diagnosis of MS
  • Evaluate the disease-modifying drug class of sphingosine 1-phosphate (S1P) receptor modulators for patients with MS regarding recent efficacy and safety data
  • Discuss strategies to individualize management to optimize outcomes for patients with MS

Post a comment to this article